Intravenous immune globulins: an update for clinicians

Knezevic-Maramica, Irina; Kruskall, Margot S.

doi:10.1046/j.1537-2995.2003.00519.x

Cited by 160 publications

(138 citation statements)

References 253 publications

(365 reference statements)

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…High-dose Ig, widely used in solid organ transplantation in highly sensitized individuals, has multiple immunomodulatory effects, including enhanced clearance of antibody, complement modulation, and inhibition of FcR-mediated clearance of cells. 32 Splx was performed after priming but prior to transplantation in an attempt to reduce alloantibody levels and eliminate splenic RES clearance of antibody-coated BM cells that may occur despite FcR blockade with mIg. To test these strategies, B6 mice were primed on day Ϫ56 against BALB/c alloantigen.…”

Section: Engraftment Can Be Achieved By the Combination Of Mega-bm Cementioning

confidence: 99%

Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients

Taylor

Ehrhardt

Roforth

et al. 2006

Blood

112

View full text Add to dashboard Cite

Multiply-transfused individuals are at higher risk for BM rejection. We show that whereas allosensitization resulted in the priming of both cellular and humoral immunity, preformed antibody was the major barrier to engraftment. The generation of cross-reactive alloantibody led to rejection of BM of a different MHC-disparate strain. Imaging studies indicated that antibody-mediated rejection was very rapid (< 3 hours) in primed recipients, while T-cell-mediated rejection in nonprimed mice took more than 6 days. Antibody-

show abstract

Section: Engraftment Can Be Achieved By the Combination Of Mega-bm Cementioning

confidence: 99%

Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients

Taylor

Ehrhardt

Roforth

et al. 2006

Blood

112

View full text Add to dashboard Cite

show abstract

“…a) It is generally administered at a dose of 400-500 mg/ kg every 3-4 weeks for prophylaxis against recurrent infections in primary immune deficiencies (6,29,30).…”

Section: ) Replacement Treatmentmentioning

confidence: 99%

“…c) In acquired immune deficieny in the childhood: It may be used at a dose of 0.2-0.4 g/kg every 4 weeks for treatment in opportunistic infections related with hypogammaglobulinemia, recurrent bacterial infections and/or inefficient antibiotic and antiretroviral treatment in HIV positive children (29,30).…”

Section: ) Replacement Treatmentmentioning

confidence: 99%

Use of intravenous immunoglobulin in pediatric practice

Zülfikar

Koç

2015

Turk Arch Ped

View full text Add to dashboard Cite

“…Statistical data confirms that immunoglobulins available today are safe. In this class of drugs there have been no reports of the transmission of blood-borne infections for over 30 years.…”

Section: Techniques Used To Protect Immunoglobulins From Pathogensmentioning

confidence: 99%

Immunoglobulins and Their Use in Children

Łaguna¹,

Gołębiowska-Staroszczyk²,

Trzaska³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Immunoglobulin preparations are one of the products of the human plasma fractionation, where the plasma is obtained, in accordance with WHO guidelines from at least 1,000 donors. These preparations contain all IgG subclasses with various antigen characteristics. In clinical practice these drugs are used as replacement therapy in patients with primary and secondary immunodeficiencies as well as immunomodulatory therapy in many autoimmune diseases and systemic inflammatory diseases. Here we present characteristics of i.v. polyvalent, human immunoglobulin preparations available on the Polish market and the possibilities of their use in clinical practice, in children with hematological diseases. Considering the very low consumption of immunoglobulin preparations in our country as compared to other European countries, we would like to draw the attention of medical professionals, especially pediatricians and haematologists, to the benefits that stem from the use of these drugs in the therapy of children with haematological diseases. Our work will also facilitate the choice of an optimal polyvalent human immunoglobulin preparation for a particular patient (Adv Clin Exp Med 2015, 24, 1, 153-159).

show abstract

Intravenous immune globulins: an update for clinicians

Cited by 160 publications

References 253 publications

Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients

Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients

Use of intravenous immunoglobulin in pediatric practice

Immunoglobulins and Their Use in Children

Contact Info

Product

Resources

About